FIU Researchers Discover New Way to Extend Immune Cell Lifespan and Effectiveness in Cancer Therapy

Researchers at Florida International University (FIU) have discovered a new method to extend the lifespan and effectiveness of immune cells used in CAR-T therapy, a treatment that has transformed the management of blood cancers like leukemia and lymphoma. The findings, reported in a recent study, address a critical limitation of CAR-T therapy: its inability to sustain efficacy against solid tumors and its eventual failure in blood cancers.

CAR-T therapy involves engineering a patient's T cells to recognize and attack cancer cells. While highly effective initially, the therapy often loses potency over time as the immune cells become exhausted or die. The FIU team identified a way to enhance the persistence and activity of these cells, potentially widening the therapeutic window. This preclinical breakthrough could lead to more durable responses in patients and extend the benefits of CAR-T therapy to solid tumors, which have remained largely resistant.

The study comes at a time when multiple academic institutions and biotech companies are racing to improve cell-based immunotherapies. Among them is Calidi Biotherapeutics Inc. (NYSE American: CLDI), which is developing its own approaches to enhance cancer-fighting cells. The convergence of research efforts underscores the growing interest in overcoming the barriers that limit current immunotherapies.

The implications of this discovery are significant. If validated in clinical trials, the method could improve outcomes for patients with hard-to-treat cancers and reduce the need for repeated treatments. It also opens the door to combining this approach with other therapies, such as checkpoint inhibitors, to boost the immune system's ability to fight tumors.

However, experts caution that the research is still in preclinical stages, and further studies are needed to confirm safety and efficacy in humans. The FIU team plans to advance their work toward clinical testing, aiming to translate the laboratory findings into tangible benefits for patients.

This development is part of a broader trend in the biotechnology sector, where companies and academic labs are leveraging insights from immunology to create next-generation cell therapies. The full details of the study can be found in the original press release from BioMedWire.